Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals Encapsulated Cell Therapy platform for the potential treatment of Macular Telangiectasia Type 2, with a projected PDUFA goal date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Jennifer Lim, MD, FARVO, FASRS, gives an update on the phase 2 DAVIO 2 trial comparing EYP-1901 with aflibercept at the annual ASRS meeting in Stockholm, Sweden.
Richard B. Rosen, MD, from the New York Eye and Ear Infirmary of Mount Sinai discussed his presentation on sickle cell retinopathy and the measurement with dynamic OCT angiography and quad-fusion adaptive optics imaging at the annual ASRS meeting in Stockholm, Sweden.
Paolo Antonio Silva, MD, discusses his presentation on diabetic retinopathy lesion types and distribution on ultra-widefield imaging and the risk for disease worsening over time at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
Danny A. Mammo, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on intraocular pressure outcomes following suprachoroidal triamcinolone acetonide in patients with glaucoma at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
The 2-year Phase III data presented at the American Society of Retina Specialists 2024 in Stockholm, Sweden, show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.
Data in early-stage patients was presented at 42nd American Society of Retina Specialists Annual Scientific Meeting, being held in Stockholm, Sweden.
The purpose of the study was to determine if experience affects the surgeons’ dexterity response to pharmacologic and behavioral interventions.
Researchers indicate that minimally invasive treatment with NurExon Biologic’s ExoPTEN showed functional restoration of damaged eyes to healthy levels in animals.
Carl C Awh, MD, FASRS, sat down with Hattie Hayes, Editor of Ophthalmology Times Europe, to discuss the first readout of the Phase 3 PAGODA trial at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
Rishi P. Singh, MD, sat down with Sydney Crago, Editor of Modern Retina, to discuss his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
Durga Borkar, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on Fas inhibition with ONL1204 for the Treatment of Geographic Atrophy and the first-time results From a Phase 1b study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
Theodore Lang, MD, MS, sat down to discuss his presentation on the FARETINA-DME Study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
Answers to common questions that can help kick-start the journey into the metaverse to learn from the many virtual educational meetings and conference opportunities while mingling with colleagues worldwide.
Martin Zinkernagel, MD, PhD, sat down with Hattie Hayes, Editor of Ophthalmology Times Europe, to discuss his time on the sustainability expert panel Study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
Carl Danzig, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the 72-Week results from the Phase 3 BALATON and COMINO trials at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
Srinivas Sai Kondapalli, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the predictive role of outer retinal tubulations in lesion growth for subfoveal and non subfoveal geographic atrophy at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
Scott Xiao, co-founder and CEO of Luminopia, sat with Ophthalmology Times to discuss the PUPiL Registry and how the VR treatment for children with amblyopia works and can revolutionize amblyopia treatment.
6E10 combined with local prophylaxishas been selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks.
Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, spoke with attendees, who shared which topics they are most looking forward to discussing at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.
Attendees shared which topics they are most looking forward to discussing at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.
4D-150 Is being evaluated in wet age-related macular degeneration (AMD).
Jennifer Lim, MD, FARVO, FASRS, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on differential artery-vein analysis in eyes with diabetic retinopathy and improvements on the OCTA classification using artificial intelligence at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
The key factor may be the control of inflammation.
The company’s Spectralis OCTA module with SHIFT technology offers a tool for the diagnoses and management of retinal diseases.
Scientists from the International Centre from Translational Eye Research used multiwavelength laser Doppler holography to assess blood flow in various layers of the human retina in vivo, which may impact the diagnosis of circulatory disorders.
This marks 21 years in a row the hospital has been top-ranked by the US News & World Report in the field of ophthalmology.
Investigators conducted a case-control study to investigate the corneal topography parameters and biomechanics in patients with alopecia areata
Claes H. Dohlman, MD, PhD, has been recognized globally as the founding father of modern corneal science, He was instrumental in driving research investigations to help better understand the structure and function of the cornea.
EyeBio is developing a pipeline of clinical and preclinical candidates for the prevention and treatment of vision loss associated with retinal vascular leakage.
